Effects of attention-deficit hyperactivity disorder on growth in children and adolescents: A systematic review and meta-analysis

Table 2 Characteristics of included studies with regard to the impact of medications for attention-deficit hyperactivity disorder on growth

Ref.	Study design	Country	Sample size	Age (year)	Female (%)	ADHA drug	Dose	Duration of medication
Deng et al[42], 2021	Retrospective study	China	86	8.9	17.4	MPH and ATX	MPH: 18 mg/day; ATX: Weight < 70 kg, 0.5 mg/kg/day, weight > 70 kg, 40 mg/day	6 months
Çevikaslan et al[41], 2021	Retrospective study	Turkey	31	7.3	0	MPH	18 mg/day	6 months
Spencer et al[30], 2005	Retrospective study	United States	419	10.6	22.2	MPH	1.2 mg/kg/day	2 years
Sund and Zeiner[29], 2001	Retrospective study	Norway	91	-	0	AMP and MPH	-	5 years
Díez-Suárez et al[39], 2017	Retrospective study	Spain	342	10.7	19.9	MPH	1.25 mg/kg/day	2 years
Mellström et al[28], 2020	Retrospective study	Sweden	724	10	27.2	MPH	0.81 mg/kg/day	3 years
Fast et al[43], 2021	Retrospective study	Sweden	44	9.9	25	MPH or lisdexamfetamine	-	1 year
Germinario et al[35], 2013	Prospective study	Italy	1758	-	11.4	MPH and ATX	MPH: 0.48 mg/kg/day; ATX: 38.7 mg/day	2 years
Mei et al[44], 2022	Prospective study	China	155	8	37.58	ATX	0.5 mg/kg/day	3 months
Spencer et al[31], 2007	Retrospective study	United States	1312	11	23.5	ATX	0.5 mg/kg/day	5 years
Gurbuz et al[38], 2016	Prospective study	Turkey	89	9.75	0	ATX	0.5 mg/kg/day	3 months
Jahangard et al[40], 2017	RCT	Iran	42	8.54	28.57	MPH + RISP	MPH + RISP (1 mg/kg/d + 0.5 mg/d)	2 months
Lee et al[27], 2022	Retrospective study	South Korea	82	8.17	22	MPH	-	2 years

ADHD: Attention-deficit hyperactivity disorder; MPH: Methylphenidate; ATX: Atomoxetine; AMP: Amphetamine; RISP: Risperidone.